Eltrombopag Powder, For Suspension
NDC Package 31722-301-32

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Eltrombopag (eltrombopag olamine) powders is a medication used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. This formulation utilizes a powder, for suspension delivery system. Marketed by Camber Pharmaceuticals, Inc., this product is identified by NDC 31722-301 and is authorized under FDA application ANDA216620.

Identification & Billing

NDC Package Code
31722-301-32
Package Description
1 CARTON in 1 KIT / 30 PACKET in 1 CARTON (31722-301-31) / 1 POWDER, FOR SUSPENSION in 1 PACKET (31722-301-25)
Product Code
31722-301
11-Digit Billing Format
31722030132
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 1859498 - eltrombopag 25 MG Powder for Oral Suspension
  • RxCUI: 1859498 - eltrombopag (as eltrombopag olamine) 25 MG Powder for Oral Suspension
  • RxCUI: 2058980 - eltrombopag 12.5 MG Powder for Oral Suspension

Clinical Specifications

Proprietary Name
Eltrombopag
Non-Proprietary Name
Eltrombopag Olamine
Substance Name
Eltrombopag Olamine
Dosage Form
Powder, For Suspension - An intimate mixture of dry, finely divided drugs and/or chemicals, which, upon the addition of suitable vehicles, yields a suspension (a liquid preparation containing the solid particles dispersed in the liquid vehicle).
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
ELTROMBOPAG OLAMINE 25 mg/1
Pharmacologic Class
Usage Information
This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

Regulatory & Marketing

Labeler Name
Camber Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA216620
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-13-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 31722-301-32 identifies a specific commercial package of 1 carton in 1 kit / 30 packet in 1 carton (31722-301-31) / 1 powder, for suspension in 1 packet (31722-301-25) of Eltrombopag, a human prescription drug labeled by Camber Pharmaceuticals, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This powder, for suspension is formulated for oral use and contains eltrombopag olamine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Camber Pharmaceuticals, Inc. on May 13, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

How is this Camber Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 31722030132. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
31722-301-32
11-Digit CMS (5-4-2)
31722-0301-32

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.